Two-year phase III trial to investigate the long-term cardiovascular safety of tesofensine.

Trial Profile

Two-year phase III trial to investigate the long-term cardiovascular safety of tesofensine.

Planning
Phase of Trial: Phase III

Latest Information Update: 31 May 2011

At a glance

  • Drugs Tesofensine (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 31 May 2011 New trial record
    • 26 May 2011 The design of the pivotal phase III programme for tesofensine was revised based on feedback from the US FDA and the EMA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top